We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00894114
First Posted: May 6, 2009
Last Update Posted: May 28, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
This study is designed to determine whether patients previously primed with Ad5 of MRKAd5 HIV-1 gag vaccine respond better when boosted with ALVAC-HIV vaccine than when boosted with MKRAd5 HIV-1 gag vaccine.

Condition Intervention Phase
HIV-1 Infection Biological: V520 Biological: Comparator: ALVAC-HIV vaccine Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Probe Study of the Safety, Tolerability, and Immunogenicity of a 1-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC-HIV (vCP205) Vaccine in Healthy Adults Who Previously Received a 3-Dose Regimen of MRKAd5, Ad5, or Placebo in Merck V520 Protocols 007 or 012

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Safety and tolerability of ALVAC-HIV or MRKAd5 HIV-1 vaccine in subjects who previously received a 3-dose regimen of Ad5 HIV-1 gag vaccine measured by number of injection-site adverse experiences (AE), non serious systemic AE, lab AE, serious AE. [ Time Frame: Injection-site AE up to 5 days after vaccination, non-serious systemic AE and Lab AE up to 29 days after vaccination, serious AE for the entire study period (Week 260). ]

Secondary Outcome Measures:
  • immunogenicity of a single-dose regimen of the ALVAC-HIV vaccine or MRKAd5 HIV-1 vaccine measured by various assays [ Time Frame: 4 weeks following vaccination ]

Enrollment: 250
Study Start Date: May 2003
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Stratum 1
Placebo recipients in the parent protocol (Merck V520 Protocols 007 or 012) will receive ALVAC-HIV Vaccine
Biological: Comparator: ALVAC-HIV vaccine
A single dose 0.1 intramuscular injection
Experimental: Stratum 2
Nonresponders who received active vaccine in parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
Biological: V520
MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
Biological: Comparator: ALVAC-HIV vaccine
A single dose 0.1 intramuscular injection
Experimental: Stratum 3
Low responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
Biological: V520
MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
Biological: Comparator: ALVAC-HIV vaccine
A single dose 0.1 intramuscular injection
Experimental: Stratum 4
High responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
Biological: V520
MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
Biological: Comparator: ALVAC-HIV vaccine
A single dose 0.1 intramuscular injection

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject was previously enrolled in Merck HIV Vaccine study V520 Protocol 007 or 012, and received the complete 3-dose regimen during participation
  • Subject is in good general health
  • Subject is not infected with HIV
  • Subject agrees not to donate blood during the first 52 weeks of the study
  • Subject agrees not to donate sperm during the first 12 weeks of the study
  • Subject who is of reproductive potential agrees to use an acceptable method of birth control through Week 12 of the study

Exclusion Criteria:

  • Subject has been administered immune globulin or blood product 3 months prior to receiving study vaccination
  • Subject has been vaccinated with a live virus vaccine in the past 30 days
  • Subject has been vaccinated with an inactivated vaccine in the past 14 days
  • Subject has an active medical disease
  • Subject is taking daily required prescription drugs
  • Female subject is pregnant, breastfeeding or expecting to conceive
  • Subject is positive for HIV
  • Subject has used injection drug within the past year
  • Subject has a sexual partner that is infected with HIV
  • Subject has a sexual partner that is an active injection drug user
  • Subject has been treated for or diagnosed with a new sexually transmitted disease in the past 6 months
  • Subject engaged in unprotected intercourse with more than 2 persons in the previous 6 months
  • Subject engaged in protected intercourse with more than 4 persons in the previous 6 months
  • Subject has previously participated in an HIV vaccine clinical trial (other than Merck V520 Protocols 007 and 012)
  • Subject weighs less than 110 lbs.
  • Subject has a recent history of alcohol abuse
  • Subject intends to donate blood in the first 52 weeks of the trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00894114


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00894114     History of Changes
Other Study ID Numbers: V520-019
2009_585
First Submitted: May 4, 2009
First Posted: May 6, 2009
Last Update Posted: May 28, 2015
Last Verified: May 2015

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs